Sarepta remains top franchise pick over 2019 at Cantor Fitzgerald

Cantor Fitzgerald analyst Alethia Young thinks the pivotal micro-dystrophin design will be in line with Sarepta Therapeutics’ “fairly detailed” description. She expects a potential data readout in 2020 and reiterates an Overweight rating on the shares with a $217 price target. Her base case assumes $1.6B in sales for Sarepta’s gene therapy micro-dystrophin. Sarepta remains the analyst’s top franchise pick over 2019 as she believes the company “still has catalysts beyond micro-dystrophin that are unappreciated by the Street.”
https://thefly.com/landingPageNews.php?id=2827585